Geneva, May 20 -- International Clinical Trials Registry received information related to the study (ACTRN12625000416493) titled 'A Study to Evaluate Tobevibart+Elebsiran in Chronic Hepatitis Delta Virus (HDV) Infection (ECLIPSE 1)' on May 7.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Primary Sponsor: Vir Biotechnology, Inc.
Condition:
Chronic Hepatitis Delta Virus (HDV) Infection
Chronic Hepatitis Delta Virus (HDV) Infection
Infection - Other infectious diseases
Intervention:
Mode of delivery: face to face
Number of times/duration/dose: tobevibart (300mg) + elebsiran (200mg) subcutaneous injections every 4 weeks for up to 240 weeks
Location: Administered at the clinical ...